Scientists are exploring the possibility of having the popular HIV prevention injection Lenacapavir in a formulation dispensed once a year. The drug, first approved in 2025 and whose uptake is reported to be high in Uganda as a twice-yearly Pre-Exposure Prophylaxis (PrEP), according to Senior Researcher Dr Flavia Matovu Kiweewa, could soon be available as a single dose. Matovu, who was the lead researcher in clinical trials of the drug in Uganda…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.